The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
* Deal to bring EpiPen, Viagra, Lipitor under one company
* Mylan CEO Heather Bresch to retire
* Combined revenue seen at $19 bln-$20 bln in 2020 (Adds details about Upjohn debt offering, Breakingviews link)
July 29 (Reuters) - Pfizer Inc has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV, a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.
The move, which brings blockbuster treatments Viagra and Lipitor under one umbrella with Mylan's EpiPen, is part of a years-long effort by Pfizer to split into three parts - innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare. Pfizer agreed in December to combine its consumer health business with GlaxoSmithKline Plc's.
The combined company, which will get a new name, is expected to have 2020 revenue of $19 billion to $20 billion, with free cash flow expected to be more than $4 billion.
The pharmaceutical industry has been under intensifying pressure from lawmakers, including President Donald Trump, to keep prices down for U.S. consumers, which has limited profits and led to recent deals, such as Bristol-Myers Squibb Co's plan to buy Celgene Corp and AbbVie Inc's acquisition of Allergan Plc.
The new company, to be based in the United States and incorporated in Delaware, will be led by Michael Goettler, president of Pfizer's Upjohn unit, which sells Pfizer's older drugs that have lost patent protection.
Upjohn will issue $12 billion of debt at or before the separation, with proceeds going to Pfizer. Pfizer said it plans to use that cash to pay down its own debt.
Mylan said Chief Executive Heather Bresch, who took the helm in 2012 and faced intense political pressure over the high price of EpiPen, will retire after the deal closes. Mylan Chairman Robert Coury will become executive chairman of the new company.
"We think it is clear Mylan needed to do something to change direction," Wells Fargo analyst David Maris said, adding that the deal is also recognition that Pfizer wanted out of generics.
Pfizer's older drugs business has a much higher operating margin than Mylan's, Maris added.
Mylan, which had a market value of $9.5 billion prior to Monday's announcement, last year said it would review its business as it grapples with lower prices of generic drugs and declining sales of its EpiPen emergency allergy treatment.
In 2015, Mylan fended off a takeover attempt from rival Teva Pharmaceutical Industries that would have valued the company at around $40 billion. Based on Monday's share price, the company is worth around $11 billion.
EpiPen sales fell sharply after Mylan was heavily criticized for steep price hikes on its device that delivers a life-saving shot epinephrine to treat severe allergic reactions. Bresch was called to testify before Congress in 2016, as the controversy put Mylan at the center of the ongoing U.S. debate over the high cost of prescription medicines.
Mylan's shares have lost about a third of their value in 2019 through Friday's close. The stock was up more than 12.9% at $20.84 on Monday, while Pfizer slipped 2% to $42.23.
Pfizer CEO Albert Bourla and his predecessor Ian Read have been saying for more than a year that the company would eschew large, transformative deals because of confidence in the strength of its pipeline.
But if the Mylan and GSK deals both close, the company will have shed two large businesses to tighten its focus on newer, patent-protected innovative medicines.
Pfizer CFO Frank D'Amelio said on a conference call that the streamlined company will grow sooner and faster beginning in 2020 than it would have otherwise.
Under terms of the agreement, Pfizer shareholders will own 57% of the new company and Mylan shareholders the rest. Each Mylan share will be converted into one share of the new company under the all-stock deal.
Revenue from the Upjohn unit in the second quarter was $2.81 billion, accounting for a fifth of Pfizer's total sales. Mylan brought in revenue of $2.85 billion in the same quarter.
Pfizer, which acquired Upjohn as part of its 2002 purchase of Pharmacia for $60 billion, will separate Upjohn in a tax-free spinoff and combine with Mylan.
Once the deal closes, the new company will have about $24.5 billion of total debt outstanding.
Separately, Pfizer reported its quarterly results on Monday, a day earlier than planned. The company cut its profit and revenue forecast for the year, largely due to the joint venture with GSK last year.
(Reporting by Michael Erman in New York and Ankur Banerjee and Tamara Mathias in Bengaluru; Additional reporting by Saumya Sibi Joseph; Editing by Arun Koyyur and Bill Berkrot)